Irbesartan Xiromed

Irbesartan, the active ingredient in Irbesartan Xiromed, is an angiotensin II receptor blocker (ARB) presented as an oral tablet for systemic use. It lowers blood pressure and reduces cardiovascular risk in adults with hypertension, diabetic kidney disease, or other related conditions.

GNH USA supplies Irbesartan Xiromed as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand. Customers benefit from reliable supply chains and professional technical support.

Irbesartan is used to manage conditions related to the renin‑angiotensin system, primarily hypertension and its complications.

Hypertension: reduces systolic and diastolic blood pressure, helping achieve target levels. Diabetic nephropathy: slows progression of kidney damage in patients with type 2 diabetes. Cardiovascular risk reduction: lowers the risk of stroke, myocardial infarction, and other major cardiovascular events.

Irbesartan may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Dizziness - Headache - Fatigue - Nausea - Abdominal discomfort - Back pain

Serious or Rare Side Effects: - Angioedema - Severe hypotension - Acute renal impairment - Hyperkalemia - Hepatic injury - Neutropenia

When prescribing Irbesartan, clinicians should consider several precautionary measures to ensure safe use.

Renal function: assess baseline renal function and monitor periodically. Electrolytes: monitor serum potassium, especially in patients with renal impairment or on potassium‑sparing diuretics. Pregnancy: avoid use in the second and third trimesters due to risk of fetal toxicity. Concomitant drugs: adjust dose when combined with strong CYP2C9 inhibitors. Hypotension: caution in volume‑depleted patients; monitor blood pressure after initiation. Store at ambient temperature below 25°C: keep in the original container, protect from moisture and light.

Irbesartan can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Potassium‑sparing diuretics (e.g., spironolactone): may cause dangerous hyperkalemia. - Aliskiren (in diabetic patients): increased risk of renal dysfunction, hypotension, hyperkalemia. - Strong CYP2C9 inhibitors (e.g., fluconazole): may raise irbesartan plasma levels. - Dual renin‑angiotensin system blockade (e.g., ACE inhibitors, other ARBs): risk of renal impairment and hyperkalemia.

Moderate Interactions (Monitor Closely): - NSAIDs: may reduce antihypertensive effect and affect renal function. - Lithium: may increase lithium levels, risk of toxicity. - Diuretics (loop or thiazide): may enhance hypotensive effect.